Bausch Health Companies Inc. (BHC) Earnings Call Transcripts
Bausch Health Companies Inc.'s Latest Earnings Call - May 20, 2026
In the Q1 2026 earnings call for Bausch Health Companies Inc. (BHC:US), management reported a continued positive trajectory with revenue growth for the 12th consecutive quarter, driven by strong performance in the Salix franchise and the Solta business. Total revenue for the quarter was $1.2 billion, exceeding expectations, while EBITDA is expected to improve due to strategic acquisitions and operational efficiencies. Management maintained guidance for operating cash flow in the range of $1.2 billion to $1.275 billion for the year, indicating stable cash generation despite anticipated headwinds from the IRA rebate affecting Xifaxan.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $1.2B (beat) |
| Operating Cash Flow Guidance | $1.2B to $1.275B (inline) |
| EBITDA Growth | expected to improve (positive) |
| Salix Revenue Growth | strong growth (positive) |
| Solta Volume Growth | 52% (positive) |
| Debt Discount | under $1B (positive) |
Guidance from management
Management maintained its operating cash flow guidance for 2026 at $1.2 billion to $1.275 billion, indicating stable expectations despite potential headwinds.
What management said
In terms -- so right now, in the D.C. district, okay, that's -- but then you have Norwich, what we call Norwich 2, which is that case in New Jersey. So there's many factors, it's multifactorial playing out here on these 2 cases. Again, there's no trial date set for the New Jersey case. I don't want to speculate of what's going to occur with the Federal Circuit in D.C, but then there's a second case. I don't know ho...
Yes. That's -- it's a good question. But the skinny label has been an issue. there. I think that what I just would say is that in the end, we are -- we believe in our intellectual property, and we're defending it. And we'll have to wait and see what the Federal Circuit says.
What analysts pressed on
Analysts expressed concerns regarding the potential impact of the IRA rebate on Xifaxan's revenue and the timeline for resolving ongoing litigation with Teva. There were also questions about the sustainability of growth in Solta and the implications of the Bausch + Lomb separation.
Main topics on the call
- Revenue Growth Acceleration — Bausch Health reported $1.2 billion in revenue for Q1 2026, marking a 12th consecutive quarter of growth. CEO Thomas Appio emphasized, "the execution on all these assets that are part of Bausch Health" has been critical ...
- Salix Franchise Performance — The Salix franchise, particularly Xifaxan, continues to be a significant revenue driver with management expecting to maintain market exclusivity until the end of 2027. CFO JJ Charhon noted, "the commercial execution... h...
- Solta Business Growth — The Solta business reported a remarkable 52% volume growth, with a strong performance in China following the acquisition of a distributor. Appio stated, "this asset has the opportunity to continue to power growth for the...
- Capital Structure and Debt Management — Management highlighted the need to deleverage the balance sheet further, with Charhon indicating, "we are overlevered, and we have to delever the balance sheet further." This underscores the company's focus on financial ...
Read the full Bausch Health Companies Inc. transcript (May 20, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Bausch Health Companies Inc.
Bausch Health Companies Inc. (BHC) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on NYSE and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 52 calls on record spanning January 13, 2020 to July 29, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 52 Bausch Health Companies Inc. earnings call transcripts on record, spanning January 13, 2020 to July 29, 2026. Based on this history, Bausch Health Companies Inc. reports quarterly. The most recent call on file is dated July 29, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- BHC
- Exchange
- NYSE
- Country
- US
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 52
- First call
- January 13, 2020
- Most recent
- July 29, 2026
- Reporting cadence
- quarterly